Out of concern for the health of the entire MassBio community, this event has been cancelled.
Digital transformation has hit Pharma R&D. Global Regulatory bodies are aligning on their demands for electronic data and submissions. We will explore how cos. are approaching & best practices.
The digital transformation imperative has hit pharmaceutical R&D. Global biopharma regulatory bodies have taken note as they align even more than ever on their demands for electronic data and submissions as well as on regulatory requirements both pre- and post- approval. For regulatory affairs leaders and professionals this evolution on how we conduct business is game changing as the function moves from pulling together dossiers from documents and spreadsheets to creating electronic submissions derived from digital data sources and conducting real-time monitoring and ownership of product, clinical, and safety data. The benefit of this change for regulatory departments is tighter relationships across their organizations, providing competitive advantage for their companies and attaining more strategic seats at the management and executive level tables. In this forum we will explore how regulatory affairs leaders are approaching digital transformation in their respective company and their recommendations to the audience of best practices. We’ll get insights from data experts / strategic services partners helping to accelerate adoption of digital innovation for their clients.
Unless otherwise specifically stated in relation to each and any of the events listed on this page, the MLSC does not host or sponsor these events. The MLSC has no oversight or responsibility for the venue, content or host-organization related to these events. The MLSC has no affiliation with the organizations listing events or with the events, and provides this content and information as a convenience to visitors to the MLSC website.
